Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improvement and was generally well tolerated over 54 weeks in patients with type 2 diabetes. Additional new data from investigational studies presented also showed that JANUVIA significantly improved blood sugar control in patients with type 2 diabetes when added to a sulfonylurea, glimepiride (dual combination therapy), or when added to a sulfonylurea and metformin (triple combination therapy). Additional data were presented at the meeting regarding the efficacy and safety of JANUVIA.

JANUVIA is a selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances a natural body system, called the incretin system, which helps to regulate glucose by affecting the beta cells and alpha cells in the pancreas. JANUVIA is the first and only DPP-4 inhibitor to be approved and marketed in the United States for patients with type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus. JANUVIA is also indicated to improve glycemic control, in combination with metformin or a thiazolidinedione (TZD), in patients with type 2 diabetes when the single agent alone plus diet and exercise do not provide adequate glycemic control. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. There are no contraindications for JANUVIA.

Sitagliptin is also a component of JANUMET(TM) (sitagliptin/metformin HCl), the first and only tablet combining a DPP-4 inhibitor and metformin for the treatment of type 2 diabetes. JANUMET is indicated, as an adjunct to
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:5/23/2013)... May 23, 2013  Omeros Corporation (NASDAQ: ... New Drug Application (IND) to evaluate OMS824 in ... Food and Drug Administration (FDA). OMS824 selectively inhibits ... of the brain linked to a wide range ... and schizophrenia. OMS824 has shown promising results in ...
(Date:5/23/2013)... 2013  Inhibikase Therapeutics, Inc., an emerging leader ... will present new results on its antiviral program ... by the PML Consortium (composed of Pfizer, Bristol-Meyers ... is the causative agent of Progressive Multifocal Leukoencephalopathy ... an extended release formulation, can clear JC polyomavirus ...
(Date:5/23/2013)... May 23, 2013 InspireMD, ... the leader in embolic protection stents, today announced ... Acute ST Elevation Reperfusion) trial demonstrating that the ... and drug eluting stents in all-cause mortality in ... from the trial were presented at the InspireMD ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... the launch of the endogo® HD, a mobile medical ... , The endogo® HD is a breakthrough device ... novel, web application; allowing physician-to-patient sharing, synchronization of patient ... secured connection to a referring doctor, anytime, anywhere. , ...
... Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD ... Ph.D., to the Company,s board of directors. Dr. Keltner ... a privately-held biotechnology company developing a late-stage, light-activated therapy ... also CEO of EPISTAT, an international healthcare technology transfer, ...
Cached Medicine Technology:Envisionier Announces the Launch of the endogo(R) HD, a Mobile Medical Imaging Platform for Capturing, Storing, and Sharing Endoscopic Multimedia 2Raptor Pharmaceutical Expands Board of Directors 2Raptor Pharmaceutical Expands Board of Directors 3Raptor Pharmaceutical Expands Board of Directors 4Raptor Pharmaceutical Expands Board of Directors 5
(Date:5/23/2013)... 2013 The vast majority of Americans ... control over their level of physical activity, the healthfulness ... are actually taking that control. Those are among ... Foundation’s 2013 Food & Health Survey. , According to ... to have “a great deal of control” or “complete ...
(Date:5/23/2013)... 23, 2013 Click here to read ... start-ups are increasingly seeing their success develop through ... companies, according to new research carried out by ... The company has compiled its research into a series ... of the research have shown the general trend that ...
(Date:5/23/2013)... Jeanne Ettelson, president of Beyond OCD , ... free OCD support group in Chicago. Launched in ... the group is lead by psychologists who specialize in ... group participants to learn accurate information about OCD, Cognitive ... in Beyond OCD’s support group benefit from being ...
(Date:5/23/2013)... Tickets announces that Paul McCartney will be performing ... This well known ticket website has slashed prices across ... fans see Sir Paul live in concert. Jan, the ... offering the customer appreciation code SAVE for additional savings on ... also a huge McCartney fan and plans to see him ...
(Date:5/23/2013)... should ensure that kids get at least one ... their health and boost performance in school, according ... studies show 60 minutes of vigorous to moderate-intensity ... that only about 50 percent of school-aged kids ... report from the Institute of Medicine. The ...
Breaking Medicine News(10 mins):Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2
... of Michigan Comprehensive Cancer Center suggest that drugs may be ... of cancer cells , raising hope for the development of ... many different cancer types. ,During the study, the ... but not missing, in some cancer cells. They found that ...
... has succeeded in drastically reducing anonymous and undocumented gun ... controls to gun shows reveals a study in ... gun shows in California and 20 shows in Arizona, ... major outside sources for guns used in crime in ...
... groups described how they had quickly fallen into a vicious ... stressed which they felt would adversely affect their chances ... more of a chore than a pleasure. ,As ... the women showed how their response fell into one of ...
... songbirds have a distinct right-brain response to the sound of ... ,Researchers at the Methodist Neurological Institute (NI) in Houston ... functional MRI to find out the results. ... future research on songbird models of speech disorders such as ...
... may seem like a good way to beat the ... increase chances of skin cancer . ,"Overexposure during ... It's could cause not just gastroenteritis, but also increase ... of the Indian Cancer Society. ,She said ...
... parts industry, which suffered two recent scams, is now under ... . According to official reports, the billion-dollar industry was examined ... a doubling of FDA inspections. ,From the FDA ... and accordingly, the 153 searches, have uncovered no morbid secrets. ...
Cached Medicine News:Health News:Drugs may Help Turn on Gene Switched Off in Cancer 2Health News:Tougher Gun Show Controls in California Slash Sales of Weapons Linked to Crime 2Health News:Research Shows How Women Deal With the Stress When Trying for a Baby! 2Health News:Research Shows How Women Deal With the Stress When Trying for a Baby! 3Health News:Bird Song Study Provides Clues to Human Speech Disorders 2Health News:Wearing Shorts, Sleeveless Clothes Could Make You Prone to Skin Cancer 2Health News:Body Parts Industry Of U.S Under Investigation 2
... Oximeter is a Pulse Oximeter and Sensor in ... pulse rate and pulse strength measurements on patients ... a large LED display, one button keypad and ... in use, makes it ideal for emergency, hospital ...
The automated and pivoting M2 hand-piece incorporates two powerful, independent electric motors : one controls the blade oscillation at 15,000 RPM and the second controls the high-torque advance of t...
Engineered for high volume surgical efficiencies, the Bausch & Lomb Hansatome Microkeratome, a corneal resection instrument, features an automated pivoting motion that provides smooth, resistance-fre...
... designed to be as easy to use ... many of its features, including CPR Coaching ... Home Defibrillator is an automated external defibrillator ... by untrained users. Although small and lightweight ...
Medicine Products: